A Phase 3 interventional study of Oral Lenacapavir (LEN) and Subcutaneous (SC) Lenacapavir (LEN) in Pre-Exposure Prophylaxis of HIV Infection, sponsored by Gilead Sciences. Active, not recruiting at 28 sites in 2 countries. Open to female participants aged 16 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.
Sponsored by Gilead Sciences · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.
Among the 65 studies testing emtricitabine in HIV Infections, this one has the largest enrollment of the 63 interventional ones that give a count, is one of 2 that started in 2021, is one of 17 in phase 3, and was the 57th registered.
4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.
Browse HIV Infections studies →4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:
CAN Community Health · Sites in United States
Ages 18+
Instituto Mexicano del Seguro Social · Sites in Mexico
Ages 18+ · Men only
University College, London
Ages 4 wk–14 yrs
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
Ages 18+
By country, each count listing its studies:
Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.
This study: 16 Years to 25 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 15 · Phase 3 19 · Phase 4 22
First in 1999; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,368 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.
Median enrollment 100 across the 63 interventional studies. Of the 48 that completed or were terminated, 22 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 65 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
84 studies in HIV Infections by Gilead Sciences: 2 open now, 8 under way, 4 of them phase 3. Of 71 finished, 28 (39%) have results posted.
Among the 84 studies in HIV Infections by Gilead Sciences, this one has the largest enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 79th registered.
Gilead Sciences’s HIV Infections studies by the year they started, since 1999.
1 of the studies testing emtricitabine in HIV Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07476339CAN Community HealthREINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE | 2027-06-17 |
Add it to your calendar (.ics) → With an account.
Among the 65 studies testing emtricitabine in HIV Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 84 in HIV Infections:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) and emtricitabine/tenofovir alafenamide (F/TAF) in preventing HIV infection, in adolescent girls and young women (AGYW).
The primary objective of this study is to evaluate the efficacy of LEN and F/TAF for HIV-1 PrEP in AGYW at risk of HIV-1 infection.
Key Inclusion Criteria:
Incidence Phase
Randomized Phase
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive lenacapavir (LEN) 927 mg injection, every 26 weeks starting on Day 1 for up to approximately 52 weeks. Participants will also receive loading dose of LEN 600 mg, tablet, once daily on Day 1 and Day 2. Participants will receive placebo to match (PTM) emtricitabine/tenofovir disoproxil fumarate (F/TDF) or PTM emtricitabine/tenofovir alafenamide (F/TAF), once daily, up to approximately 52 weeks.
Drug: Oral Lenacapavir (LEN) · Drug: Subcutaneous (SC) Lenacapavir (LEN) · Drug: PTM F/TAF · Drug: PTM F/TDF
Participants will receive F/TAF, once daily up to approximately 52 weeks. Participants will also receive PTM LEN injection, every 26 weeks, starting on Day 1 up to approximately 52 weeks. Participants will receive PTM LEN tablet, once daily on Day 1 and Day 2.
Drug: F/TAF · Drug: Placebo SC LEN · Drug: PTM Oral LEN
Participants will receive F/TDF, once daily up to approximately 52 weeks. Participants will also receive PTM LEN injection, every 26 weeks starting on Day 1 up to approximately 52 weeks. Participants will receive PTM LEN tablet, once daily on Day 1 and Day 2.
Drug: F/TDF · Drug: Placebo SC LEN · Drug: PTM Oral LEN
After completion of the Blinded phase, participants will be offered entry into the LEN OLE Phase. Participants randomized to LEN will continue to receive LEN 927 mg injection, every 26 weeks until LEN becomes available or the sponsor elects to discontinue the study, whichever occurs first. Participants randomized to F/TAF or F/TDF will receive LEN 927 mg injection on OLE Day 1, Week 26, and every 26 weeks thereafter. Participants will also receive LEN 600 mg tablet on OLE Days 1 and 2.
Drug: Oral Lenacapavir (LEN) · Drug: Subcutaneous (SC) Lenacapavir (LEN)
Participants who prematurely discontinue study drug in the randomized blinded phase will transition into the PK Tail Coverage phase. Participants will receive F/TDF, once daily, for 78 weeks beginning 26 weeks after the last LEN injection.
Drug: F/TDF
Tablets administered orally without regard to food
Also known as: GS-6207
Administered via SC injections
Also known as: GS-6207, Yeztugo®, Yeytuo®
Drug pages: Emtricitabine · Tenofovir alafenamide
Tablets administered orally
Also known as: Descovy®
Tablets administered orally
Also known as: Truvada®
Administered via SC injections
Tablets administered orally
Tablets administered orally
Tablets administered orally
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.
Time frame: Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set
HIV-1 incidence per 100 PY for LEN and F/TAF was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.
Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.
Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.
Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Randomized Blinded Phase: Percentage of Participants Adherent to F/TAF in HIV-1 Diagnosed Participants and Their Matched Controls
A participant's adherence to F/TAF was measured by tenofovir diphosphate (TFV-DP) in dried blood spot (DBS) samples, where \<450 fmol/punch associates with an adherence of \<2 days per week. The data is reported in two categories: low adherence (\<2 days per week) and not low adherence (\>= 2 days per week).
Time frame: When at least 50% of the participants completed 52 weeks of follow-up after randomization or permanently discontinued from the study (maximum 143 weeks)
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAEs were defined as 1 or both of the following: * Any adverse events (AEs) leading to premature discontinuation of study drug, or * Any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. * An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. The severity of the AEs was graded using the division of AIDS (DAIDS) toxicity grading scale version 2.1. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines : Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, Grade 5 indicates death. Percentages were rounded off.
Time frame: Up to 165 weeks
Randomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.
Time frame: Up to 165 weeks
8402 participants were screened. Out of 8402, 8094 participants had at least 1 non-missing HIV-1 diagnosis based on HIV test results from a central laboratory. Therefore, 8094 participants were considered for screening in the Incidence Phase and were included in the All Screened Set.
| Milestone | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Open-Label Extension (OLE) Phase: LEN | OLE Phase: F/TAF | OLE Phase: F/TDF |
|---|---|---|---|---|---|---|
| Started | 2148 | 2147 | 1073 | 0 | 0 | 0 |
| Randomized phase safety analysis set | 2140 | 2135 | 1070 | 0 | 0 | 0 |
| Completed | 1900 | 1853 | 898 | 0 | 0 | 0 |
| Not completed | 248 | 294 | 175 | 0 | 0 | 0 |
| Withdrew: Withdrew consent | 108 | 109 | 64 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 100 | 100 | 66 | 0 | 0 | 0 |
| Withdrew: Hiv-1 infection | 4 | 45 | 21 | 0 | 0 | 0 |
| Withdrew: Investigator's discretion | 14 | 11 | 16 | 0 | 0 | 0 |
| Withdrew: Randomized but never treated | 10 | 10 | 3 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 5 | 8 | 3 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 6 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 3 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance with study drug | 2 | 4 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrew assent | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Open-Label Extension (OLE) Phase: LEN | OLE Phase: F/TAF | OLE Phase: F/TDF |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 1893 | 1768 | 866 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 1893 | 1768 | 866 |
| Withdrew: Still on study | 0 | 0 | 0 | 1893 | 1768 | 866 |
bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was \> 75 copies/mL of blood. HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit: * Positive HIV-1/2 differentiation Ab, OR * Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR * HIV-1 RNA quantitative test ≥200 copies/mL.
| HIV-1 events per 100 person-years | Participants Screened for HIV-1 in Incidence Phase |
|---|---|
| Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY) | 2.407 (1.815 to 3.191) |
HIV-1 incidence per 100 PY for LEN and F/TAF was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Incidence Phase: All Screened Participants With Non-missing HIV-1 Diagnosis |
|---|---|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN and F/TAF Compared to Participants in All Screened Set | 0.000 (0.000 to 0.190) | 2.018 (1.435 to 2.759) | 2.407 (1.815 to 3.191) |
HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF |
|---|---|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN, F/TAF and F/TDF | 0.000 (0.000 to 0.190) | 2.018 (1.435 to 2.759) | 1.685 (0.963 to 2.737) |
A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.
| HIV-1 events per 100 person-years | Randomized Blinded Phase: Lenacapavir |
|---|---|
| Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN | 0.000 (0.000 to 0.214) |
A participant's adherence to F/TAF was measured by tenofovir diphosphate (TFV-DP) in dried blood spot (DBS) samples, where \<450 fmol/punch associates with an adherence of \<2 days per week. The data is reported in two categories: low adherence (\<2 days per week) and not low adherence (\>= 2 days per week).
| percentage of participants | Randomized Blinded Phase: F/TAF (Participants With HIV-1 Diagnosis) | Randomized Blinded Phase: F/TAF (Matched Controls - Participants With No HIV-1 Diagnosis) |
|---|---|---|
| Low (< 2 days/Week) | 91.9 | 65.9 |
| Not Low (>= 2 days/Week) | 8.1 | 34.1 |
TEAEs were defined as 1 or both of the following: * Any adverse events (AEs) leading to premature discontinuation of study drug, or * Any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug. * An AE was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily had a causal relationship with the treatment. The severity of the AEs was graded using the division of AIDS (DAIDS) toxicity grading scale version 2.1. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines : Grade 1 indicates a mild event, Grade 2 indicates a moderate event, Grade 3 indicates a severe event, Grade 4 indicates a potentially life-threatening event, Grade 5 indicates death. Percentages were rounded off.
| percentage of participants | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF |
|---|---|---|---|
| Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 90.8 | 86.6 | 85.3 |
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The DAIDS Toxicity Grading Scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.
| percentage of participants | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF |
|---|---|---|---|
| Randomized Blinded Phase: Percentage of Participants With Grade 3 or Higher Laboratory Abnormalities | 7.2 | 6.3 | 7.4 |
Collected over All-Cause Mortality: Up to 165 Weeks; Adverse Events: Up to 165 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Randomized Blinded Phase: Lenacapavir | 0/2,148 (0%) | 81/2,140 (3.8%) | 1,827/2,140 (85.4%) |
| Randomized Blinded Phase: F/TAF | 7/2,147 (0.3%) | 105/2,135 (4.9%) | 1,646/2,135 (77.1%) |
| Randomized Blinded Phase: F/TDF | 1/1,073 (0.1%) | 44/1,070 (4.1%) | 794/1,070 (74.2%) |
| Event | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF |
|---|---|---|---|
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 18/2140 | 30/2135 | 12/1070 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/2140 | 1/2135 | 4/1070 |
| MalariaInfections and infestations | 3/2140 | 5/2135 | 0/1070 |
| Intentional self-injuryPsychiatric disorders | 3/2140 | 4/2135 | 1/1070 |
| Suicide attemptPsychiatric disorders | 2/2140 | 4/2135 | 0/1070 |
| GastritisGastrointestinal disorders | 0/2140 | 1/2135 | 2/1070 |
| Humerus fractureInjury, poisoning and procedural complications | 0/2140 | 0/2135 | 2/1070 |
| Lower limb fractureInjury, poisoning and procedural complications | 0/2140 | 0/2135 | 2/1070 |
| MigraineNervous system disorders | 0/2140 | 0/2135 | 2/1070 |
| Foetal distress syndromePregnancy, puerperium and perinatal conditions | 4/2140 | 3/2135 | 1/1070 |
| Event | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF |
|---|---|---|---|
| Injection site noduleGeneral disorders | 1415/2140 | 376/2135 | 202/1070 |
| Injection site painGeneral disorders | 731/2140 | 583/2135 | 264/1070 |
| HeadacheNervous system disorders | 327/2140 | 373/2135 | 165/1070 |
| Genitourinary chlamydia infectionInfections and infestations | 352/2140 | 365/2135 | 148/1070 |
| Urinary tract infectionInfections and infestations | 344/2140 | 338/2135 | 181/1070 |
| Upper respiratory tract infectionInfections and infestations | 344/2140 | 335/2135 | 146/1070 |
| NauseaGastrointestinal disorders | 164/2140 | 249/2135 | 146/1070 |
| VomitingGastrointestinal disorders | 144/2140 | 253/2135 | 115/1070 |
| Vaginal dischargeReproductive system and breast disorders | 203/2140 | 221/2135 | 112/1070 |
| Vulvovaginal candidiasisInfections and infestations | 176/2140 | 193/2135 | 87/1070 |
Participants from the Randomized Blinded Phase Safety Analysis Set were analyzed.
| Age, Categorical(Participants) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| <=18 years | 287 | 256 | 125 | 668 |
| Between 18 and 65 years | 1853 | 1879 | 945 | 4677 |
| >=65 years | 0 | 0 | 0 | 0 |
| Age, Continuous(years) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| Mean | 21 ± 2.2 | 21 ± 2.1 | 21 ± 2.1 | 21 ± 2.1 |
| Sex: Female, Male(Participants) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| Female | 2140 | 2135 | 1070 | 5345 |
| Male | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 2140 | 2135 | 1070 | 5345 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 2137 | 2134 | 1068 | 5339 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 3 | 1 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Randomized Blinded Phase: Lenacapavir | Randomized Blinded Phase: F/TAF | Randomized Blinded Phase: F/TDF | Total |
|---|---|---|---|---|
| South Africa | 1811 | 1788 | 909 | 4508 |
| Uganda | 329 | 347 | 161 | 837 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in May 2024, 32 months.
Results were first posted in Jun 2025, 1 year after primary completion.
Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 32 months is above that.
Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Lenacapavir · Emtricitabine · Tenofovir alafenamide